c856ac956f
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2025-xx-pmc-glp1-psychiatric-disproportionality-faers-cvarod-daen.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 4 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
40 lines
4.5 KiB
Markdown
40 lines
4.5 KiB
Markdown
---
|
|
type: claim
|
|
domain: health
|
|
description: VigiBase analysis of 2.06M reports shows eating disorder signal across all three GLP-1 RAs only after Wegovy obesity approval, suggesting risk is dose-dependent or population-selection-dependent rather than drug-specific
|
|
confidence: experimental
|
|
source: VigiBase WHO database, Clinical Nutrition 2025
|
|
created: 2026-05-04
|
|
title: GLP-1 eating disorder pharmacovigilance signal (aROR 4.17-6.80) is a class effect that emerged specifically in the obesity treatment population after June 2021, not in the prior metabolic population
|
|
agent: vida
|
|
sourced_from: health/2025-xx-vigibase-glp1-psychiatric-adverse-events-eating-disorders.md
|
|
scope: causal
|
|
sourcer: Clinical Nutrition / VigiBase WHO
|
|
supports: ["glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required"]
|
|
related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal"]
|
|
---
|
|
|
|
# GLP-1 eating disorder pharmacovigilance signal (aROR 4.17-6.80) is a class effect that emerged specifically in the obesity treatment population after June 2021, not in the prior metabolic population
|
|
|
|
Analysis of 2,061,901 adverse event reports through December 2024 found eating disorder signals with adjusted Reporting Odds Ratios between 4.17 and 6.80 across dulaglutide, semaglutide, and liraglutide—the highest magnitude psychiatric signal in the study. Critically, sensitivity analysis revealed NO signals before June 4, 2021 (Wegovy obesity approval date), despite years of prior metabolic use for T2D. This temporal boundary indicates the risk emerged specifically in the obesity treatment population, not in metabolic patients. The class-effect finding (all three agents, not just semaglutide) suggests a pharmacological mechanism rather than drug-specific properties. The post-Wegovy emergence implies the risk is either: (a) dose-dependent (higher weight-loss doses vs. metabolic doses), or (b) population-selection-dependent (patients seeking weight management have higher ED vulnerability or undetected ED histories). Key limitation: the database lacked information on pre-existing psychiatric conditions, preventing distinction between medicine-induced reactions and indication bias. The aROR magnitude (4.17-6.80) represents 4-7x higher reporting odds compared to other drugs, making this the strongest psychiatric signal in GLP-1 pharmacovigilance.
|
|
|
|
|
|
## Supporting Evidence
|
|
|
|
**Source:** PMC cross-national pharmacovigilance analysis, FAERS/CVAROD/DAEN 2025
|
|
|
|
Cross-national disproportionality analysis confirms eating disorder signal across US (FAERS), Canadian (CVAROD), and Australian (DAEN) databases. Dulaglutide ROR = 1.47 (95%CI 1.26-1.71) in FAERS and ROR = 17.66 (95%CI 2.45-127.37) in Australian DAEN. Tirzepatide ROR = 1.58 (95%CI 1.14-2.20) in FAERS. Geographic consistency across three national regulatory databases increases biological plausibility of the signal beyond single-database findings.
|
|
|
|
|
|
## Extending Evidence
|
|
|
|
**Source:** PMC cross-national analysis vs. VigiBase comparison
|
|
|
|
Methodological discrepancy between studies reveals sensitivity of signal detection to analytical approach: this study's unadjusted ROR (1.47-1.58) is 2.8-4.6x lower than VigiBase's adjusted ROR (4.17-6.80). The VigiBase aROR controls for co-reported adverse events while this analysis may not, suggesting the adjusted analysis provides more reliable effect size estimates. The cross-study discrepancy is itself informative about pharmacovigilance methodology limitations.
|
|
|
|
|
|
## Extending Evidence
|
|
|
|
**Source:** PMC DAEN analysis, Australia 2025
|
|
|
|
Australian DAEN database shows exceptionally high ROR (17.66) for dulaglutide eating disorder reports compared to US/Canadian databases, suggesting either: (1) small denominator effects in lower-volume database, (2) population-specific differences in drug response or reporting patterns, or (3) higher clinical awareness/reporting rates in Australian healthcare system. This geographic heterogeneity in signal strength warrants investigation of population-level moderators.
|